Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, Improves Lung Function, Symptoms, Quality of Life and Reduces Exacerbation Rate and Risk in the Enhance-1 Phase 3 Trial of Ensifentrine in COPD

被引：0
|
作者：
Sciurba, F. C. [1 ]
Wise, R. A. [2 ]
Rheault, T. [3 ]
Bengtsson, T. [4 ]
Rickard, K. [3 ]
机构：
[1] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[2] Johns Hopkins Univ, Sch Med, Pulm & Crit Care, Baltimore, MD USA
[3] Verona Pharma Plc, Raleigh, NC USA
[4] Stat Mind AB, Lund, Sweden
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2023年 / 207卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A5006
引用
收藏
页数：2
相关论文
共 26 条
  • [21] Safety Results From Dual PDE3/4 Inhibitor Ensifentrine: Gastrointestinal and Cardiovascular Safety From a 24-week Phase 3 Trial, Enhance-2
    Siler, T. M.
    Rickard, K.
    Bengtsson, T.
    Rheault, T.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [22] Ensifentrine, A Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, Provides Effective Bronchodilation in COPD When Administered Twice Daily Over 7 Days Via a Dry Powder Inhaler
    Rheault, T.
    Rickard, K.
    Boscia, J. A.
    Bengtsson, T.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [23] Bronchodilation and Symptom Improvement with Ensifentrine, A Dual PDE3/4 Inhibitor: Sub-Group Analyses of a Four Week Randomized, Controlled Trial in Patients with COPD
    Rheault, T.
    Rickard, K.
    Bengtsson, T.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [24] Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials)
    Anzueto, Antonio
    Barjaktarevic, Igor Z.
    Siler, Thomas M.
    Rheault, Tara
    Bengtsson, Thomas
    Rickard, Kathleen
    Sciurba, Frank
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 208 (04) : 406 - 416
  • [25] Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial
    Harrison, Tim W.
    Chanez, Pascal
    Menzella, Francesco
    Canonica, Giorgio Walter
    Louis, Renaud
    Cosio, Borja G.
    Lugogo, Njira L.
    Mohan, Arjun
    Burden, Annie
    McDermott, Lawrence
    Garcia Gil, Esther
    Zangrilli, James G.
    LANCET RESPIRATORY MEDICINE, 2021, 9 (03): : 260 - 274
  • [26] LATE-BREAKING ABSTRACT: The novel inhaled dual PDE3/4 inhibitor RPL554 produces significant additional improvements in lung function when administered on top of existing standard of care in COPD patients
    Singh, Dave
    Abbott-Banner, Katharine
    Newman, Kenneth
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
123